CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Summary

This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.

Timeline

Start

2022-12

Primary completion

2024-08

Completion

2025-07

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications